{"id":"tpoxx","safety":{"commonSideEffects":[{"rate":null,"effect":"Nausea"},{"rate":null,"effect":"Headache"},{"rate":null,"effect":"Abdominal pain"}]},"_chembl":null,"_dailymed":{"setId":"fce826ab-4d6a-4139-a2ee-a304a913a253","title":"TPOXX (TECOVIRIMAT MONOHYDRATE) INJECTION, SOLUTION, CONCENTRATE TPOXX (TECOVIRIMAT MONOHYDRATE) CAPSULE [SIGA TECHNOLOGIES, INC.]"},"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"TPOXX (tecovirimat) is a small-molecule inhibitor that targets the viral protein p37, which is essential for orthopoxvirus maturation and egress from infected cells. By inhibiting p37, the drug prevents the formation of extracellular enveloped virus (EEV) particles, thereby blocking viral spread. This mechanism is effective against multiple orthopoxviruses including variola (smallpox), monkeypox, and vaccinia virus.","oneSentence":"TPOXX inhibits orthopoxvirus protein synthesis by blocking viral RNA polymerase, preventing viral replication.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T00:13:32.064Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Smallpox (variola virus infection)"},{"name":"Monkeypox (mpox)"},{"name":"Vaccinia virus infection and other orthopoxvirus infections"}]},"trialDetails":[{"nctId":"NCT05534165","phase":"PHASE3","title":"Tecovirimat in Non-hospitalized Patients With Monkeypox","status":"SUSPENDED","sponsor":"Marina Klein","startDate":"2023-08-14","conditions":"Monkeypox","enrollment":120},{"nctId":"NCT05534984","phase":"PHASE3","title":"Study of Tecovirimat for Human Mpox Virus","status":"TERMINATED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2022-09-08","conditions":"MPOX","enrollment":719},{"nctId":"NCT05559099","phase":"PHASE2","title":"Tecovirimat for Treatment of Monkeypox Virus","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2022-10-10","conditions":"Monkeypox","enrollment":597},{"nctId":"NCT06721585","phase":"","title":"Tecovirimat for Treatment of Monkeypox Virus - Study Extension Providing Standard of Care Only","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2024-07-10","conditions":"Mpox (Monkeypox)","enrollment":328},{"nctId":"NCT04957485","phase":"PHASE2","title":"Study to Assess the Safety and Immunogenicity of TPOXX® When Administered Orally for 28 Days With JYNNEOS","status":"ACTIVE_NOT_RECRUITING","sponsor":"SIGA Technologies","startDate":"2022-04-05","conditions":"Smallpox","enrollment":100},{"nctId":"NCT05597735","phase":"PHASE3","title":"Assessment of the Efficacy and Safety of Tecovirimat in Patients With Monkeypox Virus Disease","status":"RECRUITING","sponsor":"ANRS, Emerging Infectious Diseases","startDate":"2023-03-03","conditions":"Monkeypox, Mpox","enrollment":480},{"nctId":"NCT06156566","phase":"PHASE4","title":"European Trial Into Mpox Infection","status":"RECRUITING","sponsor":"Miquel Ekkelenkamp","startDate":"2024-08-09","conditions":"Monkeypox","enrollment":150},{"nctId":"NCT05380752","phase":"","title":"Tecovirimat Intravenous Treatment for Orthopox Virus Exposure","status":"NO_LONGER_AVAILABLE","sponsor":"U.S. Army Medical Research and Development Command","startDate":"","conditions":"Orthopox Virus Infection","enrollment":""},{"nctId":"NCT02080767","phase":"","title":"Tecovirimat (ST-246) Treatment for Orthopox Virus Exposure","status":"AVAILABLE","sponsor":"U.S. Army Medical Research and Development Command","startDate":"","conditions":"Smallpox, Monkeypox","enrollment":""},{"nctId":"NCT04971109","phase":"PHASE3","title":"Safety, Tolerability and Pharmacokinetics of TPOXX When Administered Orally for 28 Days","status":"COMPLETED","sponsor":"SIGA Technologies","startDate":"2022-03-29","conditions":"Smallpox","enrollment":467},{"nctId":"NCT04485039","phase":"PHASE4","title":"Drug-drug Interaction Study of TPOXX When Co-administered With Phosphate Binders","status":"COMPLETED","sponsor":"SIGA Technologies","startDate":"2022-06-08","conditions":"Smallpox","enrollment":44},{"nctId":"NCT04392739","phase":"PHASE4","title":"Safety, Tolerability and PK of TPOXX in Adults Weighing More Than 120 KG","status":"COMPLETED","sponsor":"SIGA Technologies","startDate":"2019-07-19","conditions":"Smallpox","enrollment":34},{"nctId":"NCT03972111","phase":"","title":"A Phase 4, Observational Field Study to Evaluate TPOXX in Patients With Smallpox","status":"WITHDRAWN","sponsor":"SIGA Technologies","startDate":"2020-01-01","conditions":"Smallpox","enrollment":""},{"nctId":"NCT02474589","phase":"PHASE3","title":"A Trial to Assess the Safety, Tolerability, and Pharmacokinetics of the Anti-Orthopoxvirus Compound Tecovirimat","status":"COMPLETED","sponsor":"SIGA Technologies","startDate":"2015-06-19","conditions":"Smallpox","enrollment":449},{"nctId":"NCT00431951","phase":"PHASE1","title":"Phase I, Escalating, Multiple-Dose, ST-246 Safety, Tolerability and Pharmacokinetics 21-Day Trial in Healthy Volunteers","status":"COMPLETED","sponsor":"SIGA Technologies","startDate":"2007-02","conditions":"Healthy","enrollment":30},{"nctId":"NCT00728689","phase":"PHASE1","title":"Phase I Trial of an Investigational Small Pox Medication","status":"COMPLETED","sponsor":"SIGA Technologies","startDate":"2008-08","conditions":"Orthopoxviral Disease, Smallpox, Monkey Pox","enrollment":12},{"nctId":"NCT00907803","phase":"PHASE2","title":"Safety, Tolerability, Pharmacokinetics (PK) of the Anti-Orthopox Drug, ST-246","status":"COMPLETED","sponsor":"SIGA Technologies","startDate":"2009-06","conditions":"Orthopoxviral Disease","enrollment":107}],"_emaApprovals":[],"_faersSignals":[{"count":19,"reaction":"DRUG RESISTANCE"},{"count":14,"reaction":"HEADACHE"},{"count":14,"reaction":"NAUSEA"},{"count":12,"reaction":"FATIGUE"},{"count":10,"reaction":"DIARRHOEA"},{"count":6,"reaction":"ALANINE AMINOTRANSFERASE INCREASED"},{"count":5,"reaction":"ACUTE KIDNEY INJURY"},{"count":5,"reaction":"DECREASED APPETITE"},{"count":4,"reaction":"ABDOMINAL PAIN"},{"count":4,"reaction":"DIZZINESS"}],"_approvalHistory":[{"date":"20180713","type":"ORIG","sponsor":"SIGA TECHNOLOGIES","applicationNumber":"NDA208627"},{"date":"20220518","type":"SUPPL","sponsor":"SIGA TECHNOLOGIES","applicationNumber":"NDA208627"},{"date":"20240603","type":"SUPPL","sponsor":"SIGA TECHNOLOGIES","applicationNumber":"NDA208627"},{"date":"20211123","type":"SUPPL","sponsor":"SIGA TECHNOLOGIES","applicationNumber":"NDA208627"},{"date":"20240603","type":"SUPPL","sponsor":"SIGA TECHNOLOGIES","applicationNumber":"NDA214518"},{"date":"20220518","type":"ORIG","sponsor":"SIGA TECHNOLOGIES","applicationNumber":"NDA214518"}],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["tecovirimat"],"phase":"marketed","status":"active","brandName":"TPOXX","genericName":"TPOXX","companyName":"SIGA Technologies","companyId":"siga-technologies","modality":"Small molecule","firstApprovalDate":"","aiSummary":"TPOXX inhibits orthopoxvirus protein synthesis by blocking viral RNA polymerase, preventing viral replication. Used for Smallpox (variola virus infection), Monkeypox (mpox), Vaccinia virus infection and other orthopoxvirus infections.","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":1,"withResults":1},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}